Novogen Limited (NASDAQ:KZIA) Short Interest Update

Novogen Limited (NASDAQ:KZIA) was the recipient of a large decrease in short interest during the month of January. As of January 15th, there was short interest totaling 86,745 shares, a decrease of 44.2% from the December 31st total of 155,365 shares. Based on an average daily trading volume, of 292,964 shares, the short-interest ratio is presently 0.3 days. Approximately 5.3% of the shares of the company are short sold. Approximately 5.3% of the shares of the company are short sold. Based on an average daily trading volume, of 292,964 shares, the short-interest ratio is presently 0.3 days.

Novogen Stock Performance

KZIA traded down $0.24 during trading on Friday, hitting $5.86. 293,974 shares of the company’s stock traded hands, compared to its average volume of 275,475. The company’s 50 day simple moving average is $8.78 and its two-hundred day simple moving average is $8.16. Novogen has a 12-month low of $2.86 and a 12-month high of $17.40.

Novogen (NASDAQ:KZIA) last announced its quarterly earnings results on Friday, November 7th. The company reported ($6.14) earnings per share (EPS) for the quarter. The firm had revenue of $0.59 million during the quarter.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Novogen in a report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Novogen in a research report on Thursday, January 22nd. Wall Street Zen raised Novogen to a “hold” rating in a research note on Saturday, November 22nd. Finally, Maxim Group increased their price objective on Novogen from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Thursday, October 2nd. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $19.00.

Novogen Company Profile

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.